Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

Labour Court says SIPTU should be recognised to represent Eli Lilly workers in Cork amid a growing industrial standoff ...

In a step forward for Australian dementia research, a new collaborative research project has been announced. America-based ...

Questions remain as to how FDA inspection differences between domestic and foreign drug facilities will play out.

By Nancy Lapid (Reuters) -People who take weight-loss drugs hoping to achieve the impressive results observed in large ...

The electronic health records market is experiencing robust growth, primarily driven by the increasing incidence of chronic diseases that require ong ...